SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1521-1528

  Munakata, Koji ^a   Uemura, Mamoru ^a   Takemasa, Ichiro ^a   Ozaki, Miyuki ^b   Konno, Masamitsu ^b   Nishimura, Junichi ^a   Hata, Taishi ^a   Mizushima, Tsunekazu ^a   Haraguchi, Naotsugu ^a   Noura, Shingo ^c   Ikenaga, Masakazu ^d   Okamura, S H U ^e   Fukunaga, Mutsumi ^f   Murata, Kohei ^e   Yamamoto, Hirofumi ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d OSAKA ROSAI HOSPITAL   (Japan)

^e Suita Municipal Hospital   (Japan)

^f Sakai City Medical Center   (Japan)

Author keywords

Chemoresistance; Colorectal cancer; Mammaglobin B; Radioresistance; SCGB2A1; Treatment resistance

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; MAMMAGLOBIN B; MESSENGER RNA; OXALIPLATIN; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; WNT PROTEIN;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; STATISTICAL ANALYSIS; UNIVARIATE ANALYSIS;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; MAMMAGLOBIN B; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RADIATION TOLERANCE; TRANSCRIPTION FACTORS; TWIST TRANSCRIPTION FACTOR; WNT PROTEINS;

EID: 84899125219     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2316     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Vaupel P, Briest S and Hockel M: Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 152: 334-342, 2002. (Pubitemid 34824207)
3. Sooriakumaran P and Kaba R: Angiogenesis and the tumour hypoxia response in prostate cancer: a review. Int J Surg 3: 61-67, 2005. (Pubitemid 41095569)
4. Higgins LH, Withers HG, Garbens A, et al: Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta 1787: 1433-1443, 2009.
5. Jensen RL: Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92: 317-335, 2009.
6. O'Connell MP, Marchbank K, Webster MR, et al: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov: Oct 8, 2013 (Epub ahead of print). doi: 10.1158/2159-8290.CD-13-0005 2013.
7. Zeng W, Yang D, Long T, et al: CD147 promotes melanoma progression through hypoxia-induced MMP2 activation. Curr Mol Med: Oct 3, 2013 (Epub ahead of print).
8. Lee GW, Go SI, Cho YJ, et al: Hypoxia-inducible factor-1alpha and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study. J Thorac Oncol 7: 528-534, 2012.
9. Zhang L, Huang G, Li X, et al: Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1alpha in hepatocellular carcinoma. BMC Cancer 13: 108, 2013.
10. Liu Y, Zhang JB, Qin Y, et al: PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1alpha expression and protein stability. Hepatology 58: 692-705, 2013.
11. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK and Kuppusamy P: Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 125: 2198-2204, 2009.
12. Liang D, Ma Y, Liu J, et al: The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12: 201, 2012.
13. Chang LH, Chen CH, Huang DY, Pai HC, Pan SL and Teng CM: Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1alpha translational pathway in colorectal cancer cells. J Cell Physiol 226: 1060-1068, 2011.
14. Semenza GL: Hypoxia and cancer. Cancer Metastasis Rev 26: 223-224, 2007.
15. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
16. Kizaka-Kondoh S, Inoue M, Harada H and Hiraoka M: Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94: 1021-1028, 2003. (Pubitemid 38035514)
17. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
18. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
19. Uemura M, Yamamoto H, Takemasa I, et al: Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Clin Cancer Res 16: 4636-4646, 2010.
20. Uemura M, Yamamoto H, Takemasa I, et al: Hypoxia-inducible adrenomedullin in colorectal cancer. Anticancer Res 31: 507-514, 2011.
21. Yamamoto H, Tei M, Uemura M, et al: Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer. Int J Oncol 42: 549-555, 2012.
22. Noda T, Yamamoto H, Takemasa I, et al: PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int 32: 110-118, 2012.
23. Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y and Monden M: Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Res Treat 58: 137-140, 1999. (Pubitemid 30032485)
24. Okami J, Dohno K, Sakon M, et al: Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. Clin Cancer Res 6: 2326-2332, 2000. (Pubitemid 30399199)
25. Aihara T, Fujiwara Y, Miyake Y, et al: Mammaglobin B gene as a novel marker for lymph node micrometastasis in patients with abdominal cancers. Cancer Lett 150: 79-84, 2000. (Pubitemid 30123051)
26. Ouellette RJ, Richard D and Maicas E: RT-PCR for mammaglobin genes, MGB1 and MGB2, identifies breast cancer micrometastases in sentinel lymph nodes. Am J Clin Pathol 121: 637-643, 2004. (Pubitemid 38533995)
27. Tassi RA, Bignotti E, Falchetti M, et al: Mammaglobin B expression in human endometrial cancer. Int J Gynecol Cancer 18: 1090-1096, 2008.
28. Tassi RA, Calza S, Ravaggi A, et al: Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer 9: 253, 2009.
29. Bellone S, Tassi R, Betti M, et al: Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. Br J Cancer 109: 462-471, 2013.
30. Mohrin M, Bourke E, Alexander D, et al: Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 7: 174-185, 2010.
31. Adikrisna R, Tanaka S, Muramatsu S, et al: Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 143: 234-245, 2012.
32. Miyake M, Takemasa I, Matoba R, et al: Heterogeneity of colorectal cancers and extraction of discriminator gene signatures for personalized prediction of prognosis. Int J Oncol 39: 781-789, 2011.
33. Takeno A, Takemasa I, Doki Y, et al: Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br J Cancer 99: 1307-1315, 2008.
34. Takaishi S, Okumura T, Tu S, et al: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27: 1006-1020, 2009.
35. Vermeulen L, De Sousa EMF, van der Heijden M, et al: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12: 468-476, 2010.
36. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
37. Ni J, Kalff-Suske M, Gentz R, Schageman J, Beato M and Klug J: All human genes of the uteroglobin family are localized on chromosome 11q12.2 and form a dense cluster. Ann NY Acad Sci 923: 25-42, 2000. (Pubitemid 32050853)
38. Becker RM, Darrow C, Zimonjic DB, Popescu NC, Watson MA and Fleming TP: Identification of mammaglobin B, a novel member of the uteroglobin gene family. Genomics 54: 70-78, 1998. (Pubitemid 28536195)
39. Fiegl M, Haun M, Massoner A, et al: Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol 22: 474-483, 2004. (Pubitemid 41079777)
40. Brennan DJ, Jirstrom K, Kronblad A, et al: CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12: 6421-6431, 2006. (Pubitemid 44799714)